FDA Approves Pixclara for Glioma Imaging | FET-PET Drug

The FDA has approved Pixclara (floretyrosine F 18), the first FDA-approved FET-PET imaging drug for glioma. Learn how it may help distinguish recurrent brain cancer from treatment-related changes.

The U.S. Food and Drug Administration (FDA) has approved Pixclara® (floretyrosine F 18), an amino acid positron emission tomography (PET) imaging drug designed to help differentiate recurrent or progressive glioma from treatment-related changes.

The approval was announced by Telix Pharmaceuticals on September 14, 2026. FDA records list floretyrosine F 18 under the brand name Pixclara and confirm its marketing approval for use with PET in adults and children aged 1 month and older.

What Is Pixclara?

Pixclara, also known as floretyrosine F 18 or 18F-FET, is a radioactive diagnostic imaging agent administered intravenously before a PET scan.

It is designed to target L-type amino acid transporters 1 and 2 (LAT1 and LAT2). These transport proteins can be expressed in glioma cells. The fluorine-18 radioactive isotope allows the distribution of the imaging agent to be detected with PET imaging.

According to the FDA-approved indication, Pixclara is used alongside other diagnostic evaluations to help differentiate recurrent or progressive glioma from treatment-related changes.

Why the FDA Approval Matters

Distinguishing recurrent or progressive glioma from changes caused by previous treatment can be difficult. MRI and other clinical assessments remain important parts of patient evaluation, but additional imaging information may help physicians interpret ambiguous findings.

The FDA approval makes Pixclara the first FDA-approved FET-PET imaging drug for glioma, according to Telix. FET-PET imaging has already been incorporated into international clinical practice guidance for glioma imaging.

For U.S. patients and clinicians, the approval represents a new regulatory pathway for accessing FET-PET imaging specifically for glioma.

Who Can Receive Pixclara?

The approved indication covers:

• Adults with glioma
• Pediatric patients 1 month of age and older
• Patients undergoing PET imaging to help differentiate recurrent or progressive glioma from treatment-related change
• Use of Pixclara in conjunction with other diagnostic evaluations

The FDA approval does not mean that Pixclara independently diagnoses recurrent brain cancer. PET findings need to be interpreted together with the patient's clinical history, imaging and other available diagnostic information.

Pixclara and FET-PET Imaging

FET-PET uses fluorine-18-labeled fluoroethyl-L-tyrosine, commonly referred to as 18F-FET or floretyrosine F 18.

After administration, the imaging agent is taken up through amino acid transport pathways. PET imaging can then show areas of tracer uptake, providing metabolic information that can complement anatomical imaging such as MRI.

International guidelines have recognized the role of FET-PET in the evaluation of glioma. Telix cited joint international guidance published in The Lancet Oncology as well as the NCCN Clinical Practice Guidelines in Oncology for Central Nervous System Cancers.

Safety Information for Pixclara

Like other radioactive diagnostic agents, Pixclara carries considerations related to radiation exposure.

The FDA-approved safety information warns that Pixclara PET images can be misinterpreted. A negative scan does not completely rule out recurrent or progressive glioma, while a positive scan does not by itself confirm recurrence or progression.

Equivocal uptake patterns can also occur, potentially resulting in false-positive or false-negative interpretations. For this reason, physicians are advised to correlate Pixclara PET findings with other available information, including clinical history, cross-sectional imaging and, when available, histopathology.

Pixclara also contributes to a patient's cumulative radiation exposure. Patients are advised to maintain adequate hydration and urinate frequently following administration to help reduce radiation exposure.

What Were the Reported Adverse Reactions?

Telix reported that the safety evaluation included 382 patients with gliomas, including both adults and pediatric patients.

The most frequently reported adverse reaction occurring in at least 0.5% of patients was headache, reported in 0.5% of patients.

Other reported reactions occurring in fewer than 0.5% of patients included:

• Nausea
• Injection-site reaction
• Fatigue
• Malaise

Telix reported that the safety profile observed in pediatric patients was generally consistent with the adult safety profile.

Pixclara's Potential Future Applications

The approval currently covers glioma imaging. However, Telix is also investigating Pixclara — known during development as TLX101-Px — for a potential expansion into imaging brain metastases.

The company received FDA clearance to proceed with a Phase 3 registrational study exploring this potential additional indication. This research remains investigational and does not mean Pixclara is currently approved for brain-metastasis diagnosis.

What This Means for Brain Cancer Imaging

The FDA approval of Pixclara adds another tool to the diagnostic options available for people with glioma.

Its potential value lies in providing metabolic imaging information that can complement conventional imaging. This may be particularly relevant when physicians need to determine whether an abnormality represents recurrent or progressive tumor or a change associated with previous treatment.

Importantly, Pixclara is not a replacement for MRI, pathology or clinical assessment. Instead, its approved use is as part of a broader diagnostic evaluation.

The Bottom Line

The FDA's approval of Pixclara (floretyrosine F 18) marks a significant regulatory milestone for FET-PET imaging in the United States.

As the first FDA-approved FET-PET imaging drug for glioma, Pixclara provides U.S. clinicians with an additional imaging option for evaluating recurrent or progressive glioma versus treatment-related changes.

Further research will determine how broadly Pixclara is adopted in clinical practice and whether future studies support additional uses, including imaging brain metastases.

Source: Telix Pharmaceuticals Limited and U.S. Food and Drug Administration.

Medical Disclaimer

This article is intended for general informational and educational purposes only. It is not medical advice and does not replace consultation with a qualified physician, oncologist, radiologist or other healthcare professional. FDA approval does not mean Pixclara is appropriate for every patient. Patients should discuss the potential benefits, risks and alternatives of diagnostic imaging with their healthcare provider. Pixclara PET results should be interpreted together with other clinical and diagnostic information.